The healthcare industry is one of the pivotal areas that is directly related to the sustainability and well-being of society. From cutting-edge research to nurturing the best patient-care services, the healthcare industry is for the good of humanity. As the editorial of Business Outreach Magazine, we have nothing but utmost respect for the advocates of medicine and healthcare. Our doctors, nurses, and staff in this industry work around the clock in order to provide the top-notch services that benefit patients. This piece is more than a compilation of words but a testament to the professional expertise of one of India’s most skilled radiation oncologists, Dr. Amit Jain.
Dr. Amit Jain is regarded by his patients as the best radiation oncologist in Delhi NCR. His unparalleled patient care and years of industry experience make him invaluable to the healthcare industry. Dr. Amit earned his M.B.B.S. at Dr. V.M. Medical College in 2000. Furthermore, he sharpened his skills in clinical oncology at the Tata Memorial Hospital with an MD in 2002 and cleared the DNB examination in Radiation Oncology with finals conducted at PGIMER, Chandigarh, in 2005. With a proven track record as a consultant radiation oncologist at SMH-Curie Cancer Centre, Delhi, and later as the head of radiation oncology at Valentis Cancer Hospital, Meerut, Dr. Amit Jain is cognizant of the future of oncology and the healthcare system in India. One of the most frightening diseases in modern times is “cancer.” Dr. Amit has pursued crucial research at Tata Memorial Hospital and Nanavati Hospital, which has addressed key metrics in cancer care.
Dr. Amit started the first CyberKnife S7-based Stereotactic Ablative Radiation Therapy in India
Now, many patients from abroad are also coming to benefit from this revolutionary technique. With this technique, patients can get complete treatment in 3-5 days instead of 6-7 weeks with conventional treatment. Many difficult cancers can be treated with this technique with no side effects.
In our insightful analysis of Dr. Amit Jain’s career, something that has come up often is service to society with empathy and compassion. It is unimaginable psychological pain for the patient as well as the family to tackle this monstrous disease and keep their heads straight and battle day after day. Dr. Jain understands the overwhelmingness of the situation and comes with kindness because, to him, patient care and kindness go hand in hand. Dr. Amit Jain’s reputation precedes him, with his areas of expertise including breast cancer, tumors, testicular cancer, chemotherapy, blood cancer, brain tumors, lung cancer, colon cancer, cancer pain, oral cancer, prostate cancer, liver cancer, and throat cancer.
In his more than 19 years of experience, Dr. Amit Jain tells us that honesty in his profession is what sets a good doctor apart from others. Dr. Jain’s ethics and principles in performing his job well might not have provided him with overnight success in this time of instant gratification. But while speaking to us, Dr. Jain kept stressing the importance of staying true to the purpose of becoming a doctor: saving lives. His monumental respect from patients and the industry has earned Dr. Amit Jain with awards like Active Member of the American Association of Cancer Research (AACR), Active Member of the American Society of Radiation Oncology (ASTRO), currently one of the referees of the Journal of Cancer Research and Therapeutics, the official journal of the Association of Radiation Oncologists of India (AROI), Founder Member of the Indian Society of Neuro-Oncology (ISNO), Member of the Association of Radiation Oncologists of India (AROI), and Member of the Indian Co-operative Oncology Network (ICON).
Highlighting Dr. Jain’s contributions to workshops and publications would be an understatement. A few of his presentations include Research Associate for a Phase III randomized trial of stereotactic conformal radiotherapy vs conventional radiotherapy in pediatric low-grade brain tumors at Tata Memorial Hospital; conducted research on temozolomide, concurrent and adjuvant, in glioblastoma multiforme at TMH, a prospective study on the safety and efficacy of temozolomide in pediatric brainstem gliomas with correlation to FDG-PET scans, presented at WFNO, Japan 2006; analyzed the palliative efficacy of hemibody irradiation for bony metastases in70 patients at a single institution; investigated the role of three-dimensional radiotherapy in pituitary adenomas; contributed to the analysis of patterns of outcome of carcinoma cervix from 1996 to 2000; participated in a Phase II trial of 2-deoxyglucose with hypofractionated radiotherapy in glioblastoma multiforme at TMH; Research Associate for a Phase III randomized trial of hyperthermia with radiotherapy vs hyperthermia alone in advanced head and neck cancer; and Research Associate for a Randomized Phase III trial of radiotherapy with 2-deoxyglucose vs radiotherapy alone in glioblastoma multiforme.
To our avid readership, Dr. Amit Jain says, “During my career, I learned one should not forget basic values and aims.”
